EU Approves Extended Libtayo Dosing and Faster Infusions
The European Union approved extended dosing and faster infusion times for Libtayo (cemiplimab) across skin, lung and cervical cancer indications.
The European Union approved extended dosing and faster infusion times for Libtayo (cemiplimab) across skin, lung and cervical cancer indications.